@article{open877,
          volume = {54},
          number = {1-2},
          author = {M Owais and A. K. Masood and J N Agrewala and D Bisht and C M Gupta},
            note = {Copyright of this article belongs to Wiley.},
           title = {Use of Liposomes as an Immunopotentiating Delivery System: in Perspective of Vaccine Development},
       publisher = {wiley},
            year = {2001},
         journal = {Scandinavian Journal of Immunology},
           pages = {125--132},
             url = {http://crdd.osdd.net/open/877/},
        abstract = {Liposomes have been widely used to deliver antigens to the antigen-presenting cells (APCs) and also to
modify their immunological behaviour in model animals. We recently demonstrated the potential of yeast
lipid liposomes to undergo membrane{$\pm$}membrane fusion with cytoplasmic membrane of the target cells.
Interestingly, studies in the present report revealed that antigen encapsulated in yeast lipid liposomes could
be successfully delivered simultaneously into the cytosolic as well as endosomal processing pathways of
APCs, leading to the generation of both CD41 T helper and CD81 cytotoxic T cells. In contrast,
encapsulation of same antigen in egg phosphatidyl-choline (PC) liposomes, just like its free form, has
inefficient access to the cytosolic pathway of major histocompatibility complex (MHC) I dependent antigen
presentation and failed to generate antigen specific CD81 cytotoxic T-cell response. However, both egg PC
as well as yeast lipid liposomes have elicited strong antigen specific antibody responses in immunized
animals. These results imply usage of liposome encapsulated antigen as potential candidate vaccine capable
of eliciting both cell mediated as well as humoral immune responses.}
}